Page 49 - Pharma Sector

Glenmark Pharma arm files paperwork for IPO with market regulator

Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed paperwork to go public

Pharmaceutical industry rebounds in March at 10.3% growth: Ind-Ra

This was led by volume growth of 1.6 per cent, price growth of 5.1 per cent and products launches at 3.6 per cent

New launches to prop sales recovery as GSK Pharma gets over Zinetac pain

Near-term gains may be limited given restrictions which will impact anti-infectives portfolio

This stock from Dolly Khanna's portfolio has rallied 121% so far in 2021

Dolly Khanna acquired 161,336 equity shares or 1.26 per cent stake in Neuland Lab during the quarter ended March 2021

Aarti Drugs gains 6% as board to consider buyback on March 19

In the past six months, the stock of Aarti Drugs has underperformed the market by falling 7 per cent as against a 29 per cent rally in the Sensex

Cummins India rides on exports, likely to gain as demand for power grows

Diesel engine maker projected to benefit as companies planning to build data centres seek power providers

Bharat Biotech's Covaxin gets authorisation for emergency use: V K Paul

So far 1.9 million people in the country have been given Covaxin, of whom 311 showed some side effects

Insider alleges Eli Lilly blocked her efforts to sound alarms on drug plant

Lilly is working closely with the FDA to address concerns about the factory,

PLI to drive capex in industrial sectors by 40-45 % in FY22: CRISIL report

India's GDP growth to be at 11 per cent in fiscal 2022, says report predicting two-phase economic recovery

Manufacturing to get $520-billion PLI push in next 5 years: PM Modi

Says govt aims to do away with more than 6,000 compliance requirements

A bitter pill: Domestic pharma market growth slides to 1.1% in February

Recovery slow, top drug firms post muted growth in February

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.

Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5%

Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy's Labs gained 1.7 per cent.

Govt working to improve ease of doing biz in pharma sector: Minister

The government is continuously working to reduce regulatory compliance burden on the pharma industry in a bid to improve ease of doing business in the country, Union Minister for Chemicals & Fertilisers D V Sadananda Gowda said on Thursday. Addressing the inaugural session of 'The India Pharma 2021 & India Medical Device 2021' event here, the minister also emphasised that the domestic pharma industry has the capability to achieve the target of USD 130 billion turnover by 2030. "Under the leadership of Prime Minister Narendra Modi, the government continues to strive to improve the ease of doing business in the country. Vigorous effort is on to reduce the regulatory compliance burden on the (pharma) industry," Gowda said. Minister of State for Chemicals and Fertilisers Mansukh Mandaviya said that reforms are being undertaken by the government especially in the pharmaceutical sector. "In ease of doing business we have reached 79thposition now from the earlier 145. In the pharma ..

I am sure global pharma industry will support India's WTO proposal: Goyal

The agreement on Trade-Related Aspects of Intellectual Property Rights or TRIPS came into effect in January 1995

PLI scheme to bring in investment of Rs 15,000 cr in pharma sector: Govt

The manufacturers of pharmaceutical goods registered in India will be grouped based on their global manufacturing revenue to decide the target elements for the scheme

Pharma's 3Q profitability improvement starts to taper off: Ind-Ra

The ratings agency does not expect Indian pharmaceutical companies to sustain the healthy operating margins reported during 3Q FY21 and 9M FY21

Torrent Pharma Q3 net up by 18% to Rs 297 cr even as US revenues dip

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

Torrent Pharma third quarter net profit up 18% at Rs 297 crore

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

Astrazeneca gets nod to use ant-diabetes drug for kidney disease in India

The firm said it has received marketing authorisation to use its anti-diabetic drug dapagliflozin for the treatment of patients with chronic kidney disease